

1.17 The use of Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in Primary Care.

Cherry Wynne¹, Abi Mani¹, Alison McAlister¹, Stanley D.W Miller^{1,2,3}

¹Respiratory Integrated Care, Dublin North Central, Dublin, Ireland. ²Mater Misericordiae University Hospital, Dublin, Ireland. ³School of Medicine, University College Dublin, Dublin, Ireland

Background: The Respiratory Integrated Care (RIC) nurse-led clinic in DNC accepts referrals of patients, with clinically confirmed Asthma or COPD, from General Practitioners (GP). This study explores the use of current GINA and GOLD guidelines in primary care. **Methods:** Retrospective data from referrals (July 2023 to July 2024) were reviewed. Patients with a clinically confirmed diagnosis of COPD or Asthma were included. **Results:** 108 referrals met the criteria for this study (24 Asthma, 65 COPD, and 19 Asthma/COPD). Of the 24 patients with Asthma, 2 (8.3%) were on inhaled corticosteroid (ICS) /LABA maintenance and reliever therapy (MART), 15 (62.5%) were on a short acting bronchodilator (SABA). Of the 19 patients with Asthma and COPD, 1 (5.3%) was on MART, 13 (68.4%) were on SABA. Of the 65 patients with COPD, 43 (66.2%) were on a SABA, 10 (15.4%) were on long acting muscarinic antagonist/long acting beta agonist (LAMA/LABA), and 41 (63.1%) were on a LAMA/LABA and ICS combination (LAMA/LABA/ICS). Of these 41, 37 (90.2%) had eosinophil counts >100. **Conclusion:** Results indicate a strong evidence of the use of GOLD guidelines and low incidence of patients on the GINA preferred pathway (MART). **Keywords:** Asthma, COPD **Disclosures:** **Conflict of Interest:** The Authors declare that they have no conflict of interest.